Currently, an opened clinical trial evaluating TUSC2 synergy with a third TKI generation, osimertinib, is recruiting NSCLC patients (ClinicalTrials.gov Identifier: NCT04486833). Here, TUSC2 is linked to non-small cell lung carcinoma.